Lung cancer currently causes the majority of cancer-related deaths worldwide and new treatments are in high demand. Gene therapy could be a promising treatment but currently lacks sufficient efficiency for clinical use, primarily due to limited cellular and nuclear DNA delivery. In the present study, we investigated whether it was possible to exploit the endogenous nuclear-shuttling activity by the nuclear factor kappa B (NFkB) system, which is highly prominent in many cancers as well as lung cancer. We observed that insertion of a DNA nuclear-targeting sequence (DTS) recognized by NFkB could improve plasmid nuclear delivery and enhance the therapeutic effect of a validated transcriptionally cancer-targeted suicide gene therapy system. A clear correlation between the number of inserted NFkB-binding sites and the therapeutic effect of the suicide system was observed in both small cell lung cancer (SCLC) and non-SCLC cell lines. The effect was observed to be due to elevated nuclear translocation of the suicide gene-encoding plasmids. The results show that a significant improvement of gene therapeutic efficiency can be obtained by increasing the intracellular trafficking of therapeutic DNA. This is to our knowledge the first time a DTS strategy has been implemented for suicide gene therapy.
INTRODUCTION
Worldwide, lung cancer constitutes the leading cause of cancerrelated deaths with 1.37 million lung cancer-related deaths reported in 2008.
1 Lung cancer is usually divided into two groups: small cell lung cancer (SCLC) and non-SCLC (NSCLC), of which around 15-20% is of the SCLC type. SCLC is characterized by early metastasis, aggressive progression and a neuroendocrine phenotype. The current first-line treatment consists of chemo-and radiotherapy leading to a relatively high response rate. Unfortunately, because of the development of treatment resistance, almost all patients experience relapse and the current 5-year survival rate is o10%. Despite of extensive research, little to no improvement of the survival rate for SCLC patients has been accomplished for almost three decades. 2, 3 Similarly, treatment resistance or acquired resistance also constitutes a major challenge in current NSCLC chemo-and targeted therapies. 3 New treatment strategies for both SCLC and NSCLC are thus in high demand and could include gene therapy. 4, 5 As for most cancer-targeting drugs, it is paramount that the gene therapeutic drug can be applied systemically in order to target both primary and metastasized tissue. Currently, viral vectors offers high gene expression compared with their nonviral counterparts, but the use of viral vectors is also associated with many drawbacks. A primary limitation is the induction of immune responses causing antibody-mediated clearance of the viral vector after repeated administrations, greatly limiting the therapeutic effect. 6 A nonviral vector will therefore, most likely, be necessary for repeated suicide gene therapy delivery for SCLC patients. Unfortunately, the efficacy of current systemic nonviral vectors is too low for clinical use, the reason being various extra-and intracellular barriers, each contributing to a loss of therapeutic plasmid DNA. 7 In particular, the nuclear envelope has been shown to constitute a significant barrier for nonviral vectors. The estimated half-life for plasmid DNA in the cytoplasm is currently reported to be approximately between 1 and 3 h, and because plasmids are too large to passively diffuse into the nuclei, they are 'trapped' in the cytoplasm until the cell undergoes mitosis, where the nuclear envelope is momentarily disassembled. 7, 8 This results in poor transfection efficacy of plasmids in both non-and slowly dividing cells, and also in rapidly dividing cells, which are not transfected immediately prior to mitosis. 9, 10 Although tumor cells are generally thought of as actively dividing, studies indicate that various malignancies (for example, brain, lung and liver cancer) often consist of tumors where o50% of the cells are actively dividing at a given time, providing a significant barrier to nonviral cancer gene therapy. 11 Any strategy enhancing the active transport of therapeutic DNA through the cytoplasm and into the nuclei of the target cells could therefore potentially result in higher therapeutic gene expression and a higher therapeutic index. As a consequence, various nuclear-translocation strategies have been designed to exploit the target cell's own nucleartranslocation system. One such strategy is based on binding of the therapeutic DNA to the nuclear factor kappa B (NFkB) transcription factor, which shuttles the DNA into the nucleus. Hyperactivation of the NFkB transcription factor system is a common phenomenon in many types of cancer, especially in lung cancer, making the NFkB system a good candidate for obtaining increased nuclear import of therapeutic DNA in lung cancer cells. 12, 13 Binding of NFkB requires insertion of DNA nucleartargeting sequences (DTSs) into the therapeutic DNA. These are then recognized and bound by NFkB and the DNA is transported into the nucleus.
14 This NFkB-DTS strategy has been proved to work in vitro several times. Mesika et al. 15 showed that insertion of several NFkB-binding sites resulted in a 12-fold transfection efficiency increase, of a luciferace-expressing plasmid compared with plasmids lacking such NFkB-binding sites. The same group has also shown that coupling of a functional NFkB subunit to a plasmid prior to cytoplasmic microinjection results in a significant increase of nuclear translocation compared with plasmids with no prior coupling or a plasmid coupled to a NFkB subunit with no functional nuclear-localization signal. 16 By studying how NFkB binds to DNA sequences, Goncalves et al. 17 came up with an optimized kB-binding sequence (3NF) that also proved to significantly increase the concentration of nuclear-localized plasmids compared with plasmids lacking the 3NF DNA sequence. By flanking the NFkB-binding site with specific basepairs, Goncalves et al. increased the structural fit between the NFkB transcription factor and its corresponding DNA-binding sequence. However, to date no studies have described whether the NFkB-DTS strategy improves therapeutic effect when applied together with a gene therapeutic strategy.
We have previously shown that a gene therapy system consisting of a suicide gene-encoding plasmid was able to induce SCLCspecific cytotoxicity and tumor-growth delay. 18 Two suicide genes are encoded in this system: the yeast cytosine deaminase (YCD) and yeast uracil phosphoribosyl transferase (YUPRT). Cytosine deaminase converts the nontoxic prodrug 5-fluorocytosin (5-FC) into 5-fluorouracil, which is further processed by uracil phosphoribosyl transferase, resulting in blockage of both RNA and DNA synthesis. [18] [19] [20] By controlling the expression of the suicide genes by the cancer-specific promoter insulinoma-associated 1 (INSM1), the system is transcriptionally targeted and suitable for systemic application. 21, 22 The INSM1 promoter-driven YCD-YUPRT/5-FC (super cytosine deaminase, SCD) suicide gene-therapy system has thus shown positive results both in vitro and in vivo. However, data from these studies also reveal that the suicide transgene delivery could be improved to potentially increase the clinical potential of the SCD gene-therapy system. 18 Here we show that the in vitro efficiency of INSM1-SCD/5-FC therapy can be improved significantly in several SCLC cell lines by implementing a NFkB-DTS strategy and that this effect is due to an increase in nuclear translocation of therapeutic plasmids. Furthermore, we show that the specificity of the system is not compromised by the NFkB-binding sites. Finally, we show that the effect of this system is not limited to SCLC cells, but also result in significant improvements of NSCLC gene therapy in vitro.
MATERIALS AND METHODS

Cell lines
The human SCLC cell lines: GLC16, DMS53 and NCI-H69 have been described in detail elsewhere. 21 The human non-SCLC cell line H1299 was obtained from Dr RJ Christiano (Houston, TX). The Human Adenocarcinoma A549 cell line (no. CCL-185; American Type Culture Collection, Rockvill, MD) was grown in Dulbeccoc's modified Eagle's medium supplemented with 10% fetal bovine serum and 1 Â antimycotic/antibiotic solution (Invitrogen Carlsbad, CA).
Plasmid vectors
The following plasmid vectors were used: pGL3 basic (Promega, Nacka, Sweden); EGFP-N1 (Clontech, Glostrup, Denmark); INSM1-LUC described by Pedersen et 
Transient transfections
For all cell lines, 2 Â 10 6 cells were transfected with 3 mg plasmid using 12 ml Lipofectamine 2000 in Opti-MEM Reduced Serum Medium (Invitrogen, Taastrup, Denmark) for 3 h. Adherent cells were plated 1 day prior to transfection. Transfection efficiency was estimated by the cotransfection of EGFP-N1 and visual scoring of the proportion of green cells expressing enhanced green fluorescent protein (EGFP) by fluorescence microscopy.
Luciferase assay
Cell lysates were harvested 1 day after transfection with plasmids. Cells were washed once in phosphate-buffered saline, followed by incubation with passive lysis buffer (Promega) for 1 h at room temperature. Luciferase activity was measured using the Luciferace Assay System (Promega, Mannheim, Germany). Protein concentrations were measured using the BCA protein assay (Thermo Scientific, Waltham, MA). Relative luciferase units per total mg protein was calculated and normalized to the negative control.
Cell viability assay
Cell viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay (Sigma, Broendby, Denmark) by addition of 20 ml 5 mg ml À 1 MTT solution to each well followed by 4 h incubation and addition of 100 ml solubilization buffer (10% sodium dodecyl sulfate, 0.01 mol l À 1 HCl). Absorption at 570 nm was measured the following day. Cells were replated 1 day after transfection at 25 Â 10 3 cells per well in 96-well plates and incubated for 7 days with 5-FC (50 mmol l À 1 ; Sigma) dissolved in sterile water at concentrations ranging from 0-1000 mM 5-FC.
Western blot analysis
Whole-cell lysates were prepared by sonication in ice-cold Tris-HCI 20 mmol l À 1 (pH 7.5), 2% Triton X-100 supplemented with protease and phosphatase inhibitor mixture II and III (Calbiochem, Roedovre, Denmark). Protein concentrations were determined using the bicinchoninic acid protein assay (Pierce, Herlev, Denmark) according to the manufacturer's instructions. Western blot was done using a 3-8% Tris-acetate gel, loading 20 mg protein, in the NuPAGE PreCast Gel System (Invitrogen, Taastrup, Denmark). Primary antibodies were rabbit monoclonal anti-phospho-NF-kB p65 (Ser536) (1:1000; Cell Signaling, Boston, MA, USA) and rabbit polyclonal anti-GAPDH (1:10.000; Santa Cruz Biotechnology, Heidelberg, Germany). Secondary antibody was swine anti-rabbit IgG (1:1000; DAKO, Glostrup, Denmark). Signals were detected utilizing Super-Signal West Dura extended Duration Substrate (Pierce) in the UVP Biospectrum AC imaging system (AH Diagnostics, Aarhus, Denmark).
PNA labeling of plasmids, microinjection and microscopy
In order to perform the nuclear-translocation experiments, plasmids INSM1-SCD-CY3 and INSM1-SCD-6NF-CY3 were labeled with Cy3-labeled PNA (Gene Therapy Systems, San Diego, CA, USA) as described by the manufacturer. A549 or DMS53 cells were plated on coverslips 1 or 3 days prior to microinjections. A Leica (Wetzlar, Germany) DMI6000B microscope, incubation chamber (37 1C) and an Eppendorf Femtojet were used for the microinjection experiments. The injection pressure was 120 hPa for 0.2 s in Optimization of nonviral gene delivery F Cramer et al DMS53 cells and 0.4 s in A549 cells. All plasmids used were cytoplasmically injected at a concentration of 0.5 mg ml À 1 . After microinjection, the coverslips were kept for 4 h in a humidified 37 1C incubator with 5% CO 2 . Four hours post microinjection, coverslips were washed with 1 Â phosphate-buffered saline (137 mM sodium chloride, 12 mM phosphates, 2.7 mM potassium chloride, pH 7.4), fixed with 4% paraformaldehyde in phosphate-buffered saline for 10 min, washed three times with 1 Â phosphate-buffered saline and mounted onto glass slides with 1,4-diazabicyclo[2.2.2]octane mounting media containing 4 0 ,6-diamidino-2-phenylindole nuclear stain. A Leica DMRXA2 microscope was used for fluorescence microscopy and images were captured using a Hamamatsu Orca-ER 12 bit, cooled charge-coupled device camera (Hamamatsu, Japan) and OpenLab software (Improvision, Lexington, MA).
Software and statistics
Luciferase activity assays were performed three times, each time in triplicate. All in vitro suicide gene system efficacy experiments were performed at least three times, each time in triplicate. All microinjection data were obtained from at least four experiments and based on 4100 injected cells in each setting. All experimental data are shown with mean ± 95% confidence intervals unless otherwise stated using GraphPad Prism 3.0 or 4.0 software (Innomax) for nonlinear regression analysis. All mean comparisons are based on the Student's t-test at indicated significance level.
RESULTS
The NFkB system show different activity levels in SCLC and NSCLC cell lines We have previously shown that the INSM1-SCD/5-FC suicide gene therapy system induces high cytotoxicity in SCLC cell lines and that it is superior to other suicide gene systems. We therefore chose this system for implementation of the NFkB-DTS strategy. As mentioned, the efficiency of the NFkB-DTS strategy relies exclusively on the nuclear-translocation activity of the endogenous pool of NFkB transcription factors in the target cells. Upon activation of the NFkB system, several signaling events occur, including the phosphorylation of the common subunit p65/ RELA. 23, 24 The cellular p65 phosphorylation status is therefore a reliable way to measure the NFkB-DTS nuclear-translocation potential. We thus evaluated the p65 phosphorylation level across a panel of SCLC and NSCLC cell lines (Figure 1a) . The three SCLC cell lines constitute an excellent testing model, because of the fact that the three cell lines differ in gene therapy response due to differences in INSM1-promoter activity and transfection efficiency. 18, 21, 22 Although we were previously able to achieve significant response upon INSM1-SCD/5-FC therapy in all SCLC cell lines, the response clearly correlated with levels of INSM1-promoter activity and transfection efficiency as shown by Christensen et al. 18 Besides the SCLC cell lines, we included the NSCLC cell lines A549 and H1299. Like the SCLC cell lines, A549 cells display INSM1-promoter activity (the INSM1-promoter activity was verified by EGFP and luciferase expression, data not shown), whereas H1299 cells are included as a control cell line, which does not display INSM1-promoter activity (unpublished data). Phosphorylated NFkB p65 subunits were detected in all lung cancer cell lines. In the three SCLC cell lines, we observed a distinct difference in NFkB activity. Activated NFkB was the highest in the DMS53 cell line and lowest, and almost absent, in the NCI-H69 cell line. The GLC16 cell line displayed intermediate activity compared with DMS53 and NCI-H69. Both the NSCLC cell lines, A549 and H1299, displayed a relatively high NFkB system activity. A summary of NFkB activity is listed in Figure 1b .
Insertion of NFkB-DTS in a luciferase gene-expressing plasmid results in a significant increase of luciferase activity levels in vitro compared with plasmids with no NFkB-DTS in the DMS53 SCLC cell line Next, we chose to test if the results obtained by Mesika et al. 16 could be replicated in a SCLC cell line. We therefore compared DMS53 cells transfected with the luciferase encoding plasmids; INSM1-LUC (no NFkB-binding sites inserted), INSM1-LUC-5kB (theoretically able to bind 5 0 NFkB transcription factors) and INSM1-LUC-10kB (theoretically able to bind 10 NFkB transcription factors) (see Figure 2a for cloning strategy). Twenty-four hours after transfection, the luciferase activity was measured and normalized to the INSM1-LUC mean level. As seen in Figure 2b , we observed a positive and significant correlation between the number of NFkB-binding site insertions and luciferase activity. These results indicate that increased nuclear translocation of plasmids occur upon NFkB-DTS insertions.
Insertion of NFkB-DTSs in an YCD-YUPRT (SCD) suicide gene-expressing plasmid results in a significant increase of cytotoxicity in vitro compared with plasmids with no NFkB-DTS in several SCLC cell lines In order to investigate whether implementation of the NFkB-DTS strategy could not only alter the luciferase gene expression but also alter the therapeutic efficiency of our suicide vectors, we compared cells transfected with pGL3 basic (mock), INSM1-SCD (no NFkB-binding sites inserted), INSM1-SCD-3NF (theoretically able to bind three NFkB transcription factors) and INSM1-SCD-6NF theoretically able to bind six NFkB transcription factors) (see Figure 3a , for cloning strategy). Titration of 5-FC was performed, cell proliferation post treatment was measured and IC 50 values were calculated (the IC 50 value equals the prodrug concentrations resulting in a 50% reduction of cell viability).
As seen in Figure 3b , plasmids carrying both three and six NFkB-DTS sites facilitated a significant decrease in IC 50 values of DMS53 cells compared with cells treated with the original INSM1-SCD system. Furthermore, the six-insert vector was superior to the three-insert vector (Po0.05). In the SCLC cell line GLC16, the INSM1-SCD-6NF-treated cells again demonstrated a significantly lower IC 50 value compared with cells treated with the original unmodified INSM1-SCD system. However, no significant difference in IC 50 value was observed between GLC16 cells treated with the INSM1-SCD and INSM1-SCD-3NF plasmids (Figure 3c ). In the final SCLC cell line tested (NCI-H69), no significant change in IC 50 value Optimization of nonviral gene delivery F Cramer et al was observed between any of the treatments (Figure 3d) . Thus, the sensitivity towards NFkB-DTS gene therapy corresponds with the levels of p65 phosphorylation and thereby nucleartranslocation efficacy. Importantly, the DMS53 cell line, which represents a cell type that has low sensitivity to INSM1-SCD/5-FC therapy, showed significantly improved response rates when multiple NFkB-DTS inserts were added to the suicide geneencoding plasmid.
As our SCLC suicide gene therapy specificity relies on transcriptional targeting, we hereafter decided to test whether the cancer-specific promoter activity of INSM1 was compromised by the insertions of NFkB transcription-factor-binding sites. The therapeutic efficiencies of the different plasmids were tested in the non-SCLC (NSCLC) cell line H1299 because we have previously shown that the INSM1-SCD/5-FC system does not result in any cytotoxicity in H1299 cells, although the transfection efficiency is relatively high in this cell line. 18 As showed in Figure 3e , no cytotoxicity was observed in the H1299 cells, regardless of which plasmid type was used for transfection.
Insertions of mutated NFkB-DTSs does not result in a significant increase of cytotoxicity in vitro compared with plasmids with no NFkB-DTS in DMS53 SCLC cells To validate that the increase in cytotoxicity, upon NFkB-DTS insertions, was in fact due to binding of NFkB transcription factors to the plasmids, we performed a negative control experiment. By investigating the literature, we found that especially three of the basepairs in the NFkB-DTS sequence seemed essential for binding of the two most common NFkB subunits: p50 and p65. 25 We therefore mutated these three basepairs (Figure 4a ) and repeated our viability assay in the DMS53 SCLC cell line where we had observed the greatest effect upon NFkB-DTS insertions. As seen in Figure 4b , we again register a significant increase in gene therapy efficiency when treating DMS53 cells with plasmids carrying three NFkB-DTSs compared with plasmids carrying no NFkB-DTSs. A similar significant difference in treatment efficiency could be observed between plasmids carrying three NFkB-DTSs and three mutated NFkB-DTSs. Thus, the increased cytotoxicity observed with plasmids carrying three NFkB-DTS sites is due to NFkBspecific effects.
Insertion of NFkB-DTSs results in increased nuclear translocation of INSM1-SCD plasmids in DMS53 SCLC cells Next, we chose to investigate if the increased therapeutic effect seen upon inserting NFkB-DTSs into the suicide plasmids was indeed due to increased plasmid nuclear translocation. Because the largest increase in potency was observed in the DMS53 cell line, and being the only adherent SCLC cell line of the three tested, it was chosen for microinjection studies. DMS53 cells were microinjected with either Cy3-tagged INSM1-SCD or INSM1-SCD-6NF plasmids in the cytoplasm and scored for nuclear-localized Cy3 signal 4 h later. A significant increase of both cytotoxicity and nuclear translocation can also be obtained in vitro in a NSCLC cell line upon insertion of NFkB-DTS sequences To investigate if the NFkB-DTS strategy could be further expanded for certain NSCLC cell types with INSM1-promoter activity and further validate the proof of concept, we tested the cytotoxicity and nuclear translocation of the INSM1-SCD and INSM1-SCD-6NF plasmids in the A549 NSCLC cell line. As the A549 cell line displays relatively high NFkB activity (Figure 1a) , the NFkB-DTS strategy should have the potential to increase the nuclear translocation of the INSM1-SCD-6NF compared with the INSM1-SCD plasmid. Furthermore, A549 cells display significant INSM1-promoter activity, suggesting that our suicide plasmids, containing nuclear-targeting sequences would result in higher cytotoxicity compared with cells treated with the original, DTS-free, suicide gene plasmid. As seen in Figure 6a 
DISCUSSION
In the present study, we show that implementation of a NFkB-DTS nuclear-translocation strategy results in a significant increase in therapeutic efficiency of targeted suicide gene therapy in both SCLC and NSCLC cells. This is to our knowledge the first study showing that the NFkB-DTS nuclear-translocation strategy can improve the therapeutic outcome of gene therapeutic drugs. The delivery of plasmids to the nuclei of target cells has proven to be a major barrier in nonviral gene therapy for decades. In the three SCLC cell lines, we observe a clear correlation between NFkB activity, plasmid nuclear import and therapeutic efficiency upon insertion of NFkB-binding sites. The most significant therapeutic improvement was obtained in the DMS53 cell line, which seemingly has the highest NFkB system activity. In this cell line, the 5-FC IC 50 value dropped almost 10-fold upon inserting NFkBDTSs. Similarly, we observed that INSM1-SCD-6NF plasmids were more effectively transported to the nucleus of the DMS53 cells (E68%) compared with DMS53 cells transfected with INSM1-SCD plasmids (E10%) (Figure 5c ). The significant therapeutic improvement in the DMS53 cells was lost upon the mutation of three basepairs in the NFkB-DTSs, strongly suggesting that the decrease in cell viability upon NFkB-DTSs insertions is due to utilization of the DMS53 cancer cell endogenous NFkB system. These results are of importance because this cell line displays poor sensitivity towards INSM1-SCD/5-FC therapy due to relatively low INSM1-promoter activity and transfection efficacy. Less improvement was seen in the GLC16 cells and no effect was seen in the NCI-H69 cell line where the NFkB system activity in comparison with DMS53 was moderate to low, respectively. Interestingly, these two cell lines also possess intrinsically high sensitivity towards INSM1-SCD/ 5-FC therapy and thus efficiency of suicide gene therapy is less dependent on the NFkB translocation strategy. Furthermore, the fact that the highest gain of potency was obtained in the DMS53 cell line, compared with GLC16 and NCI-H69 cells, indicates that the relationship between nuclear plasmid concentration and treatment efficiency is not linear and that a certain efficiency level for nuclear plasmid concentration may exist. Previously, studies by Cohen et al. 26 estimated that transgene expression increases only slightly with additional plasmids, once approximately 3000 plasmids have entered the nucleus. As mentioned, the transfection efficiency in the three SCLC cell lines tested in this study varies significantly (60±3% in GLC16, 45±2% in NCI-H69 and 25 ± 3% in DMS53, data not shown). It could be speculated that in the Lipofectamine 2000-based transfection method used for viability assays, this 3000 plasmid/nucleus limit is close or already has been achieved in the GLC16 and NCI-H69 cell lines and insertion of NFkB-binding sites therefore does not result in the same, or none at all, IC 50 decrease as seen in the DMS53 cell line. Another possibility or a combination of the two, for the observed differences in IC 50 reductions, could be the different INSM1-promoter activity levels in the three SCLC cell lines. In a recent study, van Gaal et al. 27 hypothesized that one important bottleneck for the plasmid transgene expression could be the strength of the promoter used for the transgene expression and that a strong promoter, for example, the CMV promoter, could saturate the expression machinery, thereby masking any increase in nuclear translocation. In support of this hypothesis, we see the smallest effect of the NFkB-DTS insert in the NCI-H69 cell line that has the relatively highest INSM1-promoter activity; in contrast, we see the largest effect in the DMS53 cell line, which has the relatively lowest promoter activity of the three SCLC cell lines tested. 22 It is, however, highly unlikely that in vivo systemic nonviral gene delivery will approach transfection efficiencies as those we observe during these specific in vitro experiments. It could be hypothesized that the majority of cancer cells will, in vivo, receive a number of plasmids that is well below the limit discussed above and therefore significant treatment efficiency could be gained by NFkB-DTS inserts. Furthermore, even though limit is reached without any DTS inserts and a cancer cell can only undergo cell death once, even small elevations of suicide gene expression are not in vain, because the 5-fluorouracil product diffuse freely out of the cancer cells and result in significant local bystander effects. 18 Far from every cancer cell in a tumor is transfected during systemic delivery. As such, even small increases in expression, due to NFkB inserts, could possibly result in an increased bystander effect.
To verify that the inserted NFkB transcription-factor-binding sites did not compromise the cancer specificity of the INSM1 promoter, we tested the construct in the NSCLC cell line H1299, which has no INSM1-promoter activity but displays a relatively high NFkB activity. No cytotoxicity was observed in the H1299 cell line upon treatment with the INSM1-SCD constructs, with or without NFkB-DTS inserts, strongly suggesting that the DTS inserts have no effect on the SCLC specificity of the INSM1 promoter (Figure 3e ). To add additional proof of concept, we decided to test the system in the NSCLC cell line A549 which displays a relative highly active NFkB system (Figure 1b) , as well as INSM1-promoter activity. We therefore expected an increase of both the nuclear translocation and treatment efficiency with the INSM1-SCD-6NF plasmids compared with the INSM1-SCD plasmids. Indeed, the 5-FC IC 50 values dropped more than 20 fold upon NFkB-DTS insertions ( Figure 6a) . As in the SCLC cell line DMS53, we also found that the INSM1-SCD-6NF plasmid was more effectively transported to the nucleus of the A549 cells (E65%) compared with A549 cells transfected with INSM1-SCD plasmids (E12%) (Figure 7c ). This indicates that the NFkB-DTS/suicide gene therapy strategy is not limited to SCLC but also could prove useful in NSCLC cell lines with a suitable expression profile.
It is also interesting to note that the two cell lines where we observe the greatest decrease in 5-FC IC 50 value upon insertion of NFkB-DTSs, DMS53 and A549 (Figures 3b and 6b ) are both adherent, in contrast to NCI-H69 and GLC16 that are both suspension cell lines. In the DMS53 and A549 cell lines, the cytoplasmic area is significantly larger than that in the NCI-H69 and GLC16, where the nuclei are surrounded only by a very scant cytoplasmic area. Because the cytoplasm is filled with dense networks like the actin cytoskeleton, microtubule network and so on, plasmids are highly restricted in their passive diffusion. 
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Plasmids could therefore potentially be exposed to a hostile DNAdegrading environment for a longer time in the dense network of a relatively large adherent cell than in the very limited cytoplasmic area of the suspension cell lines tested in the present work. Perhaps this indicates a correlation between cell morphology and effect of NFkB-DTS inserts for gene therapy, although the in vivo cell morphology might differ considerably.
The next step will be to test if these promising results can be translated to in vivo experiments, further determining the clinical relevance of the NFkB-DTS strategy. Future experiments will also include testing the activity levels of a wide panel of transcription factors in different SCLC and NSCLC cell lines to determine the potential of novel DTS sequences, which could be useful in gene therapy for lung cancer patients. As the type of lung cancer cell lines will differ from patient to patient, so will the levels of active transcription factor systems. A specific transcription factor DTS could possibly have a significant effect in one patient while prove insignificant in another. Other transcription factor candidates for increasing nuclear translocation could include members of the PAX family, especially PAX5, which has been shown to be significantly expressed in SCLC tumors and possibly involved in cancer cell survival and metastasis. 29, 30 Frequent amplification of transcription-factor-encoding genes, including c-Myc, MYCN and L-Myc, is seen in SCLC and the protein expression levels of these could therefore also be of interest. 31, 32 Recently, Dooley et al.
33
discovered a novel oncogenic transcription factor in SCLC. The Nfib gene, coding for the nuclear factor I/B, were found to be amplified in SCLC tumor-derived cell lines and thereby also constitutes a candidate for a DTS strategy. The amplification and expression of the mentioned genes varies significantly between the different lung cancer cell lines, underscoring the importance of potentially tailoring the DTS gene therapy to target each individual patient/lung cancer cell line and/or heterogeneous cancer cells population within a tumor. In summary, we show for the first time to our knowledge, that by implementing a nuclear-translocation strategy into a suicide gene therapy system developed for SCLC treatment, we are able to significantly improve the amount of cell nuclei that receive the therapeutic plasmids and thereby improve treatment efficacy for lung cancer cell lines in vitro. We further show that the NFkB-DTS strategy might also have potential in gene therapy for NSCLC cells and finally we show that the NFkB-DTS inserts do not lead to suicide gene-expression leakage. These results hold promise for increasing in vivo gene therapeutic transfection efficiencies and thus improving treatment efficiency.
